Resistance of cancer cells to conventional chemotherapy is one of the major challenges in cancer treatment, leading to disease recurrence after treatment and the emergence of aggressive cancer forms that reduce patients' quality of life and shorten their lifespan. Cancer stem cells (CSC) play a significant role in chemoresistance, as they are inherently resistant to chemotherapy and can survive aggressive treatments. Among other, in CSC expression of cysteine cathepsins B and X that are involved in numerous processes related to cancer initiation and progression is increased. Their increased activity in cancer can be selectively regulated using specific low-molecular inhibitors that effect the functional properties of CSC.
In this master's thesis, we investigated the impact of cathepsin B (nitroxoline) and X (compound Z9) inhibitors in combination with conventional chemotherapy (5-fluorouracil) on the functional properties of CSC. CSC were isolated from three breast cancer cell lines that differ in the proportion of cells with CSC phenotype (MDA-MB-231, MCF-7, and MCF 10A neoT). We evaluated the effects of the inhibitors either alone or in combination with conventional chemotherapy on intracellular and extracellular degradation of DQ-collagen IV, as well as the impact of the cathepsin B inhibitor in combination with chemotherapy on CSC invasion.
The obtained results indicate that cathepsin B and X inhibitors are effective not only against differentiated tumor cells but also against CSC. We demonstrated that the use of cathepsin inhibitors can reduce ECM degradation in CSC and their invasion. Furthermore, the results suggest that simultaneous inhibition of cathepsin B and X has a synergistic effect on reducing ECM degradation in CSC. Additionally, we showed that concurrent inhibition of cathepsins in combination with conventional chemotherapy further reduces ECM degradation and CSC invasion. The use of cathepsin B and X inhibitors, with their effect on CSC, represents a promising approach to overcome the limitations of existing antitumor therapy. By concurrently applying cathepsin B and X inhibitors with existing chemotherapy, we can enhance the effectiveness of current CSC targeted antitumor therapy, even in processes where conventional chemotherapeutics are less effective.
|